Abstract
Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with 177Lu-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
